SCHEMBL10883178

SCHEMBL10883178

NCCSSc1ccncc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
DDAH1 O94760 1/20 0.42
NOS1 P29475 1/20 0.42
KIF11 P52732 1/20 0.42
LOXL2 Q9Y4K0 4/20 0.41
CYP2D6 P10635 3/20 0.38
ALDH1A1 P00352 3/20 0.38
CYP1A2 P05177 2/20 0.38
CYP3A4 P08684 2/20 0.38
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38
HSD17B10 Q99714 1/20 0.38
TSHR P16473 2/20 0.38
THPO P40225 1/20 0.38
HRH1 P35367 2/20 0.36
MAPT P10636 4/20 0.36
EHMT2 Q96KQ7 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
LMNA P02545 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31121202 0.78 MEN1 (0.54) MEN1KMT2ADDAH1NOS1LOXL2
SCHEMBL9655918 0.77 MAPT (0.50) KIF11LOXL2CYP2D6ALDH1A1CYP1A2
SCHEMBL1540227 0.77 CYP2D6 (0.48) MEN1KMT2ADDAH1NOS1KIF11
Hydrochloric Acid SCHEMBL6896084 0.76 MAPT (0.48) KIF11LOXL2CYP2D6ALDH1A1CYP1A2
Bromide SCHEMBL11004897 0.76 CYP2D6 (0.47) MEN1KMT2ADDAH1NOS1KIF11
Hydrochloric Acid SCHEMBL9310313 0.76 CYP2D6 (0.47) MEN1KMT2ADDAH1NOS1KIF11
SCHEMBL27013269 0.74 KMT2A (0.48) MEN1KMT2ADDAH1NOS1CYP2D6
SCHEMBL18763536 0.74 MEN1 (0.48) MEN1KMT2ADDAH1NOS1CYP2D6
Hydrochloric Acid SCHEMBL10608206 0.74 MEN1 (0.43) MEN1KMT2ADDAH1NOS1CYP2D6
SCHEMBL191955 0.72 MEN1 (1.00) MEN1KMT2ADDAH1NOS1LOXL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4677111-A2 SYSTEMS, METHODS, AND COMPOSITIONS FOR SEQUENCING Ultima Genomics, Inc. (US) 2026-01-14 EP disclosed
WO-2025029957-A1 SEQUENCING REAGENTS ULTIMA GENOMICS, INC. (US) 2025-02-06 WO disclosed
WO-2024186844-A2 SYSTEMS, METHODS, AND COMPOSITIONS FOR SEQUENCING ULTIMA GENOMICS, INC. (US) 2024-09-12 WO disclosed
US-20100216695-A1 SECOND GENERATION LOW OXYGEN AFFINITY PEGYLATED HEMOGLOBINS AS OXYGEN-CARRYING PLASMA EXPANDERS NATIONAL INSTITUTES OF HEALTH 2010-08-26 US disclosed
EP-0040506-B1 REACTIVE POLYMER AND PROCESS FOR THE PREPARATION THEREOF TEIJIN LIMITED (JP) 1986-08-20 EP disclosed
US-4385169-A Reactive alpha amino acid polymer TEIJIN LIMITED (JP) 1983-05-24 US disclosed
EP-0040506-A2 Reactive polymer and process for the preparation thereof TEIJIN LIMITED (JP) 1981-11-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216695-A1 SECOND GENERATION LOW OXYGEN AFFINITY PEGYLATED HEMOGLOBINS AS OXYGEN-CARRYING PLASMA EXPANDERS HBG2, HBG1, HBB MEN1 4045/4885KMT2A 1404/4885DDAH1 2043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.